Live-cell single-molecule imaging for drug discovery
Eikon Therapeutics, led by former Merck R&D head Roger Perlmutter, uses Nobel-winning super-resolution microscopy to watch single molecules move in living cells, powering a novel drug-discovery engine.
Biotech📍 Hayward, CAFounded 2019
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Eikon Therapeutics going public?
No. Eikon Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Eikon Therapeutics' valuation in 2026?
No confirmed valuation is on record for Eikon Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Eikon Therapeutics filed an S-1?
No public S-1 is on file for Eikon Therapeutics.
Can you buy Eikon Therapeutics stock?
No. Eikon Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Eikon Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Roger Perlmutter
Founded
2019
HQ
Hayward, CA
IPO Status
private
Fundraising Status
private
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
10
6 active · 5 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Tumor, Solid
Advanced Solid Tumors · Non Small Cell Lung Cancer (Squamous or Non Squamous)
Latest trial start
2026-06-15
Name-verified against lead sponsor "Eikon Therapeutics" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
+5% vs 2026-08
Open roles
22
via greenhouse
Product-build share
55%
engineering, research, product, design
Trajectory
steady
product-led hiring — 55% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Associate Director, Clinical Study Management, EMEA/LATAMEikon Engineering Talent CommunityEikon Research Talent CommunityExecutive Director, Clinical Research (Medical Director)Senior Clinical Trial Manager, OncologySenior Clinical Trial Manager, Oncology (APAC)
Counted from Eikon Therapeutics's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.